Why the success of your HTA will rely on real world evidence

Presented by

Adam Lloyd, Eric Yu, Rita Faria

About this talk

The first in a trilogy of webinars focussed on the topic; Unlocking the value; the economic equation and part of the IMS Health Practical Insights series. While it remains the gold standard, the feasibility of large scale randomised clinical trials within a pipeline that is ever more focused on niche and personalised medicines is decreasing – particularly in the fields of rare diseases and oncology. Within the changing landscape of drug development, payers need robust evidence in order to accurately assess the value and efficacy of innovative treatments for both smaller patient populations and increasingly expensive medicines. Answering this paradigm is where real world evidence can step in. Topics covered include: •The HTA landscape – the challenges of assessing rare disease and cancer medicines •How regulators consider RWE in HTAs •Learnings from best practice in global markets •Recent case studies – successes and failures •The role of the regulator in the Cancer Drugs Fund •How RWE can assist market access

Related topics:

More from this channel

Upcoming talks (0)
On-demand talks (102)
Subscribers (25982)
pharmaphorum provides a digital podium for communicating thought leadership and innovation within pharma. Our webinars bring together different stakeholders from across the healthcare spectrum to drive fresh thinking and novel solutions that deliver better outcomes for patients.